Radiation oncology firm Accuray has garnered U.S. Food and Drug Administration (FDA) 510(k) clearance for its ClearRT helical kilovoltage CT (kVCT) imaging technology.
Integrated into the company's Radixact radiation therapy platform, ClearRT is designed to produce CT images with diagnostic-like quality, according to the vendor. It can provide helical fan-beam imaging at both kV and megavoltage (mV) wavelengths, supporting imaging requirements for patient setup and registration, Accuray said.
ClearCT is expected to be commercially available for Radixact in the spring of 2021, according to the vendor.
